ENG/中
老虎证券
行情
交易
收费
下载
优惠与活动
帮助
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
股权激励
关于
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Ipsen S.A.
47.81
+1.67
3.61%
成交量:
160.00
成交额:
7,637.30
市值:
157.96亿
市盈率:
21.90
高:
47.81
开:
47.81
低:
47.81
收:
46.15
52周最高:
47.81
52周最低:
25.11
股本:
3.30亿
流通股本:
1.12亿
量比:
0.63
换手率:
0.00%
股息:
0.41
股息率:
0.86%
每股收益(TTM):
2.18
每股收益(LYR):
2.15
净资产收益率:
10.44%
总资产收益率:
9.60%
市净率:
3.09
市盈率(LYR):
22.21
数据加载中...
总览
公司
新闻资讯
公告
益普生公布2025年上半年强劲业绩并上调全年财务指引
美通社
·
2025/08/05
益普生2025年第一季度实现稳健业绩增长并确认全年业绩指引
美通社
·
2025/04/18
在所有治疗领域强劲业绩的推动下,益普生2024年实现稳健业绩增长并确认2025年全年指引
美通社
·
2025/02/17
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠: 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投,免费实时行情与多种工具,立即开户享更多优惠!","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠: 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投,免费实时行情与多种工具,立即开户享更多优惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/IPSEY/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IPSEY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEY\",,,,,undefined,":{"symbol":"IPSEY","market":"US","secType":"STK","nameCN":"Ipsen S.A.","latestPrice":47.81,"timestamp":1772046448595,"preClose":46.145,"halted":0,"volume":160,"delay":15,"changeRate":0.03608191570050924,"floatShares":112371575,"shares":330397936,"eps":2.183055,"marketStatus":"盘后交易","change":1.665,"latestTime":"02-25 14:07:28 EST 延时","open":47.81,"high":47.81,"low":47.81,"amount":7637.300000000001,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":2.183055,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772067600000},"marketStatusCode":4,"adr":0,"adrRate":0.25,"exchange":"PINK LIMITED","adjPreClose":46.145,"volumeRatio":0.633413},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPSEY\",,,,,undefined,":{"symbol":"IPSEY","floatShares":112371575,"roa":"9.60%","roe":"10.44%","lyrEps":2.152613,"volumeRatio":0.633413,"shares":330397936,"dividePrice":0.413203,"high":47.81,"amplitude":0,"preClose":46.145,"low":47.81,"week52Low":25.11,"pbRate":"3.09","psRate":"3.41","week52High":47.81,"institutionHeld":0,"latestPrice":47.81,"eps":2.183055,"divideRate":0.008643,"volume":160,"delay":15,"ttmEps":2.183055,"open":47.81,"prevYearClose":36.3596,"prevWeekClose":46.145,"prevMonthClose":40.76,"prevQuarterClose":36.3596,"fiveDayClose":46.145,"twentyDayClose":40.97,"sixtyDayClose":36.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPSEY\",params:#limit:5,,,undefined,":[{"date":"2025-06-09","symbol":"IPSEY","amount":0.398618,"announcedDate":"2025-05-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-09","defaultRemindTime":1749475800000,"name":"Ipsen S.A.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-09","currency":"USD","dateTimestamp":1749441600000,"payDate":"2025-06-25"},{"date":"2024-07-25","symbol":"IPSEY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-05-31","symbol":"IPSEY","amount":0.235267,"announcedDate":"2024-05-20","type":"dividend","market":"US","newRecordDate":"2024-05-31","defaultRemindTime":1717162200000,"name":"Ipsen S.A.","recordDate":null,"payableDate":"2024-05-31","currency":"USD","dateTimestamp":1717128000000,"payDate":null},{"date":"2023-06-02","symbol":"IPSEY","amount":0.324045,"announcedDate":"2023-05-19","type":"dividend","market":"US","newRecordDate":"2023-06-05","defaultRemindTime":1685712600000,"name":"Ipsen S.A.","recordDate":"2023-06-27","payableDate":"2023-06-05","currency":"USD","dateTimestamp":1685678400000,"payDate":"2023-06-27"},{"market":"US","date":"2022-10-26","symbol":"IPSEY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘前","type":"earning","dateTimestamp":1666756800000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPSEY\",market:\"US\",,,undefined,":[{"executeDate":"2016-05-31","recordDate":"2016-06-02","paymentDate":"2016-07-13","value":0.177552,"currency":"USD"},{"executeDate":"2021-05-28","recordDate":"2021-06-01","paymentDate":"2021-06-09","value":0.275217,"currency":"USD"},{"executeDate":"2022-05-31","recordDate":"2022-06-01","paymentDate":"2022-06-09","value":0.315063,"currency":"USD"},{"executeDate":"2023-06-02","recordDate":"2023-06-05","paymentDate":"2023-06-27","value":0.324045,"currency":"USD"},{"executeDate":"2024-05-31","recordDate":"2024-05-31","paymentDate":null,"value":0.235267,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPSEY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPSEY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2557399040","title":"益普生公布2025年上半年强劲业绩并上调全年财务指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2557399040","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557399040?lang=zh_cn&edition=fundamental","pubTime":"2025-08-05 12:32","pubTimestamp":1754368320,"startTime":"0","endTime":"0","summary":"在此基础上,我很高兴,益普生在销售和利润方面的全年指引做了上调。\" 2025年全年指引 基于上半年强劲的业绩表现,益普生上调了2025年全年财务指引: 以固定汇率计算,总销售额增长超过7.0%。2025年7月23日,欧盟委员会批准益普生将Cabometyx用于治疗既往接受治疗的晚期神经内分泌肿瘤患者。上述所有风险因素均可能影响益普生未来达成财务目标的能力,而这些目标是基于当前可获取信息并假设宏观经济环境相对稳定的前提下设定的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4744400_ZH44400_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IPSEY","IPN","BK4007"],"gpt_icon":0},{"id":"2528906912","title":"益普生2025年第一季度实现稳健业绩增长并确认全年业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2528906912","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528906912?lang=zh_cn&edition=fundamental","pubTime":"2025-04-18 17:35","pubTimestamp":1744968900,"startTime":"0","endTime":"0","summary":"确认2025年全年财务指引。巴黎2025年4月18日 /美通社/ -- 全球特药领域生物制药公司益普生于4月16日公布了2025年第一季度的财务业绩。对益普生而言,2025年将是重要的一年,多个产品即将上市,我们的产品组合有望达成多项里程碑。\" 全年指引 益普生确认了2025年全年财务指引: 以固定汇率计算,总销售额增长超过5.0%。集团再融资 益普生于3月19日宣布成功完成其首次5亿欧元的评级公募债券发行,票面利率为3.875%,于2032年3月到期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4667912_ZH67912_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IPN","BK4007","IPSEY"],"gpt_icon":0},{"id":"2512529945","title":"在所有治疗领域强劲业绩的推动下,益普生2024年实现稳健业绩增长并确认2025年全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2512529945","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512529945?lang=zh_cn&edition=fundamental","pubTime":"2025-02-17 17:58","pubTimestamp":1739786280,"startTime":"0","endTime":"0","summary":"本年度还与Skyhawk Therapeutics签署了一项合作协议,开发用于治疗罕见神经系统疾病的RNA调节小分子药物。环境、社会和治理 2024年,益普生采取了重要步骤,以实施可持续发展战略的宏伟目标。经过密集转型项目,目前益普生全球99.8%的电力来自可再生能源。2025年财务指引 益普生为2025财年制定了以下财务指引,其中排除了潜在的后期业务开发交易的任何影响: 以固定汇率计算,总销售额增长超过5.0%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4620551_ZH20551_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4080","ADC","BK4231","IPSEY","IPN","BK4007","ALGS","BK4505","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}